Grail, a subsidiary of the DNA sequencing company Illumina, plans to introduce the first liquid biopsy test by the end of the year. Grail’s is rolling out its Galleri test, which can detect 50 types of cancer, 45 of which have no recommended screening in the U.S. Another company called Exact Sciences is developing its own multi-cancer screening test. However, it won’t be ready until 2025
